-
-
-
-
-
-
-
Lake Street Starts Kazia Therapeutics (KZIA) at Buy
-
-
-
-
-
-
-
Kazia Therapeutics regains full NASDAQ compliance
-
-
-
-
-
-
-
Kazia reports 86% tumor reduction in single breast cancer patient case
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Reports Phase 2/3 Trial Results for Paxalisib in Glioblastoma
-
-
461,032 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

